TOKYO -- Japan's health ministry is preparing to formally approve as early as Monday the manufacture and sale of an Alzheimer's drug developed by Japanese pharmaceutical company Eisai and U.S. partner Biogen.
Lecanemab, marketed as Leqembi, will be Japan's first treatment for the disease that has been shown to be effective at slowing its progression.
%2520%E3%81%AE%E3%82%B3%E3%83%94%E3%83%BC.jpg?width=178&fit=cover&gravity=faces&dpr=2&quality=medium&source=nar-cms&format=auto&height=100)
